NORDHEALTH |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.8 NOK | +15.36% |
|
+12.67% | +36.29% |
| Mar. 05 | Transcript : Nordhealth AS, Q4 2023 Earnings Call, Mar 05, 2024 | |
| Mar. 05 | Nordhealth AS Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- With an enterprise value anticipated at 58.9 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +36.29% | 242M | - | ||
| +4.36% | 32.47B | C | ||
| +14.14% | 7.45B | C- | ||
| +22.93% | 3.89B | B- | ||
| -16.29% | 3.15B | C- | ||
| -25.96% | 1.28B | B | ||
| -36.14% | 1.09B | - | ||
| -35.42% | 902M | - | ||
| -0.13% | 893M | C | ||
| -24.12% | 857M | - | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NORDH Stock
- Ratings Nordhealth
